FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 354:203-205 January 12, 2006 Number 2 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Holmes, K. K. Related Article by Riedner, G. PubMed Citation

To the Editor: In their study on the treatment of early syphilis, Riedner et al. (Sept. 22 issue)¹ concluded that the wider use of oral azithromycin should be encouraged as part of syphilis-control programs in developing countries. Whereas this conclusion would appear to be rational on the basis of the authors' results, we believe that there are other factors that should be considered before opting for such a strategy.

Although the authors acknowledged the potential for the emergence of azithromycin-resistant Treponema pallidum, ongoing monitoring for such resistance, as they suggested, requires molecular-sequencing techniques,² which are unavailable in most developing countries. . . . [Full Text of this Article]

This article has been cited by other articles:

• Zetola, N. M., Engelman, J., Jensen, T. P., Klausner, J. D. (2007). Syphilis in the United States: An Update for Clinicians With an Emphasis on HIV Coinfection. Mayo Clin Proc. 82: 1091-1102 [Abstract] [Full Text]